2024 |
Muratovic, D., Atkins, G. J., & Findlay, D. M. (2024). Is RANKL a potential molecular target in osteoarthritis?. Osteoarthritis and Cartilage, 32(5), 493-500. DOI Scopus5 Europe PMC2 |
2023 |
Muratovic, D., Findlay, D. M., Quinn, M. J., Quarrington, R. D., Solomon, L. B., & Atkins, G. J. (2023). Microstructural and cellular characterisation of the subchondral trabecular bone in human knee and hip osteoarthritis using synchrotron tomography. Osteoarthritis and Cartilage, 31(9), 1224-1233. DOI Scopus4 WoS1 |
2022 |
Ormsby, R. T., Hosaka, K., Evdokiou, A., Odysseos, A., Findlay, D. M., Solomon, L. B., & Atkins, G. J. (2022). The Effects of Vitamin E Analogues α-Tocopherol and γ-Tocotrienol on the Human Osteocyte Response to Ultra-High Molecular Weight Polyethylene Wear Particles. Prosthesis, 4(3), 480-489. DOI Scopus2 WoS1 |
2022 |
Dorraki, M., Muratovic, D., Fouladzadeh, A., Verjans, J. W., Allison, A., Findlay, D. M., & Abbott, D. (2022). Hip osteoarthritis: A novel network analysis of subchondral trabecular bone structures. PNAS Nexus, 1(5), pgac258-1-pgac258-11. DOI Scopus1 |
2022 |
Muratovic, D., Findlay, D. M., Quarrington, R. D., Cao, X., Solomon, L. B., Atkins, G. J., & Kuliwaba, J. S. (2022). Elevated levels of active Transforming Growth Factor β1 in the subchondral bone relate spatially to cartilage loss and impaired bone quality in human knee osteoarthritis. Osteoarthritis and Cartilage, 30(6), 896-907. DOI Scopus7 WoS1 Europe PMC2 |
2022 |
Hofstaetter, J. G., Atkins, G. J., Kato, H., Kogawa, M., Blouin, S., Misof, B. M., . . . Ito, N. (2022). A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene. Calcified Tissue International, 111(4), 430-444. DOI Scopus2 WoS1 Europe PMC2 |
2021 |
Lee, Y. -R., Findlay, D. M., Muratovic, D., & Kuliwaba, J. S. (2021). Greater heterogeneity of the bone mineralisation density distribution and low bone matrix mineralisation characterise tibial subchondral bone marrow lesions in knee osteoarthritis patients. Bone, 149, 1-10. DOI Scopus9 WoS4 Europe PMC4 |
2020 |
Lee, Y., Findlay, D., Muratovic, D., Gill, T., & Kuliwaba, J. (2020). Raman microspectroscopy demonstrates reduced mineralization of subchondral bone marrow lesions in knee osteoarthritis patients. Bone Reports, 12, 100269-1-100269-9. DOI Scopus6 WoS4 Europe PMC2 |
2019 |
Muratovic, D., Findlay, D. M., Cicuttini, F. M., Wluka, A. E., Lee, Y. R., Edwards, S., & Kuliwaba, J. S. (2019). Bone marrow lesions in knee osteoarthritis: regional differences in tibial subchondral bone microstructure and their association with cartilage degeneration. Osteoarthritis and Cartilage, 27(11), 1653-1662. DOI Scopus35 WoS20 Europe PMC20 |
2019 |
Ormsby, R. T., Solomon, L. B., Stamenkov, R., Findlay, D. M., & Atkins, G. J. (2019). Evidence for gender-specific bone loss mechanisms in periprosthetic osteolysis. Journal of Clinical Medicine, 9(1), 1-15. DOI Scopus6 WoS5 Europe PMC2 |
2019 |
Ormsby, R. T., Solomon, L. B., Yang, D., Crotti, T. N., Haynes, D. R., Findlay, D. M., & Atkins, G. J. (2019). Osteocytes respond to particles of clinically-relevant conventional and cross-linked polyethylene and metal alloys by up-regulation of resorptive and inflammatory pathways. Acta Biomaterialia, 87, 296-306. DOI Scopus41 WoS32 Europe PMC22 |
2019 |
Zhu, S., Zhu, J., Zhen, G., Hu, Y., An, S., Li, Y., . . . Cao, X. (2019). Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. Journal of Clinical Investigation, 129(3), 1076-1093. DOI Scopus262 WoS174 Europe PMC189 |
2018 |
Alliston, T., Hernandez, C. J., Findlay, D. M., Felson, D. T., & Kennedy, O. D. (2018). Bone marrow lesions in osteoarthritis: what lies beneath. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 36(7), 1818-1825. DOI Scopus60 WoS44 Europe PMC37 |
2018 |
Muratovic, D., Findlay, D., Cicuttini, F., Wluka, A., Lee, Y. -R., & Kuliwaba, J. (2018). Bone matrix microdamage and vascular changes characterize bone marrow lesions in the subchondral bone of knee osteoarthritis. Bone, 108, 193-201. DOI Scopus51 WoS35 Europe PMC25 |
2018 |
Yang, D., Wijenayaka, A., Solomon, L., Pederson, S., Findlay, D., Kidd, S., & Atkins, G. (2018). Novel insights into Staphylococcus aureus deep bone infections: the involvement of osteocytes. mBio, 9(2), e00415-18-1-e00415-18-10. DOI Scopus121 WoS92 Europe PMC74 |
2018 |
Yang, D., Anderson, P., Wijenayaka, A., Barratt, K., Triliana, R., Stapledon, C., . . . Atkins, G. (2018). Both ligand and VDR expression levels critically determine the effect of 1α,25-dihydroxyvitamin-D₃ on osteoblast differentiation. Journal of Steroid Biochemistry and Molecular Biology, 177, 83-90. DOI Scopus14 WoS10 Europe PMC8 |
2018 |
Kogawa, M., Khalid, K., Wijenayaka, A., Ormsby, R., Evdokiou, A., Anderson, P., . . . Atkins, G. (2018). Recombinant sclerostin antagonises effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size. American Journal of Physiology - Cell Physiology, 314(1), 53-61. DOI Scopus25 WoS20 Europe PMC15 |
2017 |
Daish, C., Blanchard, R., Gulati, K., Losic, D., Findlay, D., Harvie, D., & Pivonka, P. (2017). Estimation of anisotropic permeability in trabecular bone based on microCT imaging and pore-scale fluid dynamics simulations. Bone Reports, 6, 129-139. DOI Scopus28 Europe PMC11 |
2017 |
Thewlis, D., Fraysse, F., Callary, S., Verghese, V., Jones, C., Findlay, D., . . . Solomon, L. (2017). Postoperative weight bearing and patient reported outcomes at one year following tibial plateau fractures. Injury, 48(7), 1650-1656. DOI Scopus28 WoS17 Europe PMC14 |
2017 |
Liapis, V., Zysk, A., DeNichilo, M., Zinonos, I., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2017). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Medicine, 6(9), 2164-2176. DOI Scopus8 WoS7 Europe PMC5 |
2017 |
Clark, J., & Findlay, D. (2017). Musculoskeletal health in the context of spinal cord injury. Current Osteoporosis Reports, 15(5), 433-442. DOI Scopus18 WoS14 Europe PMC9 |
2017 |
Panagopoulos, V., Liapis, V., Zinonos, I., Hay, S., Leach, D. A., Ingman, W., . . . Evdokiou, A. (2017). Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Molecular and Cellular Endocrinology, 440(C), 8-15. DOI Scopus17 WoS15 Europe PMC13 |
2017 |
Zysk, A., DeNichilo, M., Panagopoulos, V., Zinonos, I., Liapis, V., Hay, S., . . . Evdokiou, A. (2017). Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Letters, 386, 141-150. DOI Scopus20 WoS17 Europe PMC13 |
2017 |
Gulati, K., Prideaux, M., Kogawa, M., Lima-Marques, L., Atkins, G. J., Findlay, D. M., & Losic, D. (2017). Anodized 3D-printed titanium implants with dual micro- and nano-scale topography promote interaction with human osteoblasts and osteocyte-like cells. Journal of Tissue Engineering and Regenerative Medicine, 11(12), 3313-3325. DOI Scopus86 WoS70 Europe PMC23 |
2016 |
Findlay, D., & Kuliwaba, J. (2016). Bone-cartilage crosstalk: a conversation for understanding osteoarthritis. Bone Research, 4(1), 1-12. DOI Scopus194 WoS182 Europe PMC108 |
2016 |
Saad, S., Dharmapatni, A., Crotti, T., Cantley, M., Algate, K., Findlay, D., . . . Haynes, D. (2016). Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss. Acta Biomaterialia, 30, 311-318. DOI Scopus20 WoS14 Europe PMC12 |
2016 |
DeNichilo, M., Shoubridge, A., Panagopoulos, V., Liapis, V., Zysk, A., Zinonos, I., . . . Evdokiou, A. (2016). Peroxidase enzymes regulate collagen biosynthesis and matrix mineralization by cultured human osteoblasts. Calcified Tissue International, 98(3), 294-305. DOI Scopus12 WoS11 Europe PMC9 |
2016 |
Wijenayaka, A., Prideaux, M., Yang, D., Morris, H., Findlay, D., Anderson, P., & Atkins, G. (2016). Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D₃. Journal of Steroid Biochemistry and Molecular Biology, 164, 369-373. DOI Scopus13 WoS9 Europe PMC10 |
2016 |
Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2016). Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Medicine, 5(3), 534-545. DOI Scopus25 WoS21 Europe PMC20 |
2016 |
Gulati, K., Maher, S., Chandrasekaran, S., Findlay, D., & Losic, D. (2016). Conversion of titania (TiO2) into conductive titanium (Ti) nanotube arrays for combined drug-delivery and electrical stimulation therapy. Journal of Materials Chemistry B, 4(3), 371-375. DOI Scopus41 WoS30 Europe PMC5 |
2016 |
Ormsby, R., Cantley, M., Kogawa, M., Solomon, L., Haynes, D., Findlay, D., & Atkins, G. (2016). Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis. Acta Biomaterialia, 33, 242-251. DOI Scopus60 WoS46 Europe PMC29 |
2016 |
Muratovic, D., Cicuttini, F., Wluka, A., Findlay, D., Wang, Y., Otto, S., . . . Kuliwaba, J. (2016). Bone marrow lesions detected by specific combination of MRI sequences are associated with severity of osteochondral degeneration. Arthritis Research and Therapy, 18(1), 54-1-54-11. DOI Scopus52 WoS43 Europe PMC30 |
2016 |
Prideaux, M., Findlay, D., & Atkins, G. (2016). Osteocytes: the master cells in bone remodelling. Current Opinion in Pharmacology, 28, 24-30. DOI Scopus156 WoS128 Europe PMC93 |
2016 |
Briggs, M., Kuliwaba, J., Muratovic, D., Everest-Dass, A., Packer, N., Findlay, D., & Hoffmann, P. (2016). MALDI mass spectrometry imaging of N-glycans on tibial cartilage and subchondral bone proteins in knee osteoarthritis. Proteomics, 16(11-12), 1736-1741. DOI Scopus42 WoS37 Europe PMC24 |
2016 |
Gulati, K., Johnson, L., Karunagaran, R., Findlay, D., & Losic, D. (2016). In situ transformation of chitosan films into microtubular structures on the surface of nanoengineered titanium implants. Biomacromolecules, 17(4), 1261-1271. DOI Scopus19 WoS14 Europe PMC3 |
2016 |
Prideaux, M., Schutz, C., Wijenayaka, A. R., Findlay, D. M., Campbell, D. G., Solomon, L. B., & Atkins, G. J. (2016). Isolation of osteocytes from human trabecular bone. Bone, 88, 64-72. DOI Scopus34 WoS28 Europe PMC17 |
2016 |
Gulati, K., Maher, S., Findlay, D., & Losic, D. (2016). Titania nanotubes for orchestrating osteogenesis at the bone-implant interface. Nanomedicine, 11(14), 1847-1864. DOI Scopus71 WoS57 Europe PMC28 |
2016 |
Gulati, K., Kogawa, M., Prideaux, M., Findlay, D., Atkins, G., & Losic, D. (2016). Drug-releasing nano-engineered titanium implants: therapeutic efficacy in 3D cell culture model, controlled release and stability. Materials Science and Engineering C, 69, 831-840. DOI Scopus58 WoS46 Europe PMC10 |
2016 |
Rahman, S., Gulati, K., Kogawa, M., Atkins, G., Pivonka, P., Findlay, D., & Losic, D. (2016). Drug diffusion, integration, and stability of nanoengineered drug-releasing implants in bone ex-vivo. Journal of Biomedical Materials Research Part A, 104(3), 714-725. DOI Scopus32 WoS30 Europe PMC10 |
2015 |
Wluka, A., Teichtahl, A., Maulana, R., Liu, B., Wang, Y., Giles, G., . . . Cicuttini, F. (2015). Bone marrow lesions can be subtyped into groups with different clinical outcomes using two magnetic resonance imaging (MRI) sequences. Arthritis Research and Therapy, 17(1), 270-1-270-8. DOI Scopus13 Europe PMC9 |
2015 |
Rahman, S., Ormsby, R., Santos, A., Atkins, G., Findlay, D., & Losic, D. (2015). Nanoengineered drug-releasing aluminium wire implants: comparative investigation of nanopore geometry, drug release and osteoblast cell adhesion. RSC Advances, 5(92), 75004-75014. DOI Scopus6 WoS6 |
2015 |
Ito, N., Wijenayaka, A., Prideaux, M., Kogawa, M., Ormsby, R., Evdokiou, A., . . . Atkins, G. (2015). Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Molecular and Cellular Endocrinology, 399(C), 208-218. DOI Scopus141 WoS126 Europe PMC102 |
2015 |
Wijenayaka, A., Yang, D., Prideaux, M., Ito, N., Kogawa, M., Anderson, P., . . . Atkins, G. (2015). 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Molecular and Cellular Endocrinology, 413(C), 157-167. DOI Scopus41 WoS32 Europe PMC27 |
2015 |
Clarke, M., Russell, P., Findlay, D., Sastra, S., Anderson, P., Skinner, J., . . . Davey, R. (2015). A role for the Calcitonin respetor to limit bone loss during lactation in female mice by inhibiting osteocytic osteolysis. Endocrinology, 156(9), 3203-3214. DOI Scopus47 WoS33 Europe PMC22 |
2015 |
Gulati, K., Santos, A., Findlay, D., & Losic, D. (2015). Optimizing anodization conditions for the growth of titania nanotubes on curved surfaces. Journal of Physical Chemistry C, 119(28), 16033-16045. DOI Scopus100 WoS82 |
2015 |
Gulati, K., Kant, K., Findlay, D., & Losic, D. (2015). Periodically tailored titania nanotubes for enhanced drug loading and releasing performances. Journal of Materials Chemistry B, 3(12), 2553-2559. DOI Scopus43 WoS38 Europe PMC9 |
2015 |
Rahman, S., Atkins, G., Findlay, D., & Losic, D. (2015). Nanoengineered drug releasing aluminium wire implants: a model study for localized bone therapy. Journal of Materials Chemistry B, 3(16), 3288-3296. DOI Scopus14 WoS12 Europe PMC3 |
2015 |
Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2015). Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 357(1), 160-169. DOI Scopus40 WoS36 Europe PMC32 |
2014 |
Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., Denichilo, M., . . . Evdokiou, A. (2014). Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS). Anticancer Research, 34(12), 7007-7020. Scopus6 WoS4 Europe PMC5 |
2014 |
Ito, N., Peña, A., Perano, S., Atkins, G., Findlay, D., & Couper, J. (2014). First Australian report of vitamin D-dependent rickets type I. Medical Journal of Australia, 201(7), 420-421. DOI Scopus4 WoS3 Europe PMC2 |
2014 |
Prideaux, M., Wijenayaka, A., Kumarasinghe, D., Ormsby, R., Evdokiou, A., Findlay, D., & Atkins, G. (2014). SaOS2 osteosarcoma cells as an in vitro model for studying the transition of human osteoblasts to osteocytes. Calcified Tissue International, 95(2), 183-193. DOI Scopus93 WoS79 Europe PMC56 |
2014 |
Zinonos, I., Luo, K., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2014). Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 45(2), 532-540. DOI Scopus20 WoS20 Europe PMC16 |
2014 |
Low, S., Bain, G., Findlay, D., Eng, K., & Perilli, E. (2014). External and internal bone micro-architecture in normal and Kienböck's lunates: A whole-bone micro-computed tomography study. Journal of Orthopaedic Research, 32(6), 826-833. DOI Scopus25 WoS18 Europe PMC14 |
2014 |
Findlay, D. M., & Atkins, G. J. (2014). Osteoblast-chondrocyte interactions in osteoarthritis. Current Osteoporosis Reports, 12(1), 127-134. DOI Scopus112 WoS96 Europe PMC77 |
2014 |
Stamenkov, R., Neale, S., Kane, T., Findlay, D., Taylor, D., & Howie, D. (2014). Cemented liner exchange with bone grafting halts the progression of periacetabular osteolysis. Journal of Arthroplasty, 29(4), 822-826. DOI Scopus7 WoS6 Europe PMC3 |
2014 |
Ito, N., Findlay, D., & Atkins, G. (2014). Osteocyte communication with the kidney via the production of FGF23: Remote control of phosphate homeostasis. Clinical Reviews in Bone and Mineral Metabolism, 12(1), 44-58. DOI Scopus9 WoS7 |
2013 |
Findlay, D. (2013). Long overlooked: the role of subchondral bone in osteoarthritis pathophysiology and pain. Medicographia, 35(2), 221-227. |
2013 |
Callary, S., Thewlis, D., Rowlands, A., Findlay, D., & Solomon, L. (2013). Collecting a comprehensive evidence base to monitor fracture rehabilitation: a case study. World Journal of Orthopedics, 4(4), 259-266. DOI Scopus4 WoS4 Europe PMC2 |
2013 |
Kogawa, M., Wijenayaka, A., Ormsby, R., Thomas, G., Anderson, P., Bonewald, L., . . . Atkins, G. (2013). Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. Journal of Bone and Mineral Research, 28(12), 2436-2448. DOI Scopus135 WoS113 Europe PMC81 |
2013 |
Howie, D., Neale, S., Haynes, D., Holubowycz, O., McGee, M., Solomon, L., . . . Findlay, D. (2013). Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management. Inflammopharmacology, 21(6), 389-396. DOI Scopus39 WoS30 Europe PMC23 |
2013 |
Kogawa, M., Hisatake, K., Atkins, G., Findlay, D., Enoki, Y., Sato, T., . . . Matsumoto, M. (2013). The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-kB ligand (RANKL)-induced Osteoclast differentiation. Journal of Biological Chemistry, 288(43), 31299-31312. DOI Scopus20 WoS20 Europe PMC15 |
2013 |
Welldon, K., Findlay, D., Evdokiou, A., Ormsby, R., & Atkins, G. (2013). Calcium induces pro-anabolic effects on human primary osteoblasts associated with acquisition of mature osteocyte markers. Molecular and Cellular Endocrinology, 376(1), 85-92. DOI Scopus25 WoS24 Europe PMC19 |
2013 |
Ito, N., Findlay, D., Anderson, P., Bonewald, L., & Atkins, G. (2013). Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D₃ (1,25D) on osteocyte like cells. Journal of Steroid Biochemistry and Molecular Biology, 136(1), 183-186. DOI Scopus50 WoS42 Europe PMC38 |
2013 |
Davey, R., & Findlay, D. (2013). Calcitonin: physiology or fantasy?. Journal of Bone and Mineral Research, 28(5), 973-979. DOI Scopus70 WoS62 Europe PMC37 |
2013 |
Kogawa, M., Findlay, D., Anderson, P., & Atkins, G. (2013). Modulation of osteoclastic migration by metabolism of 25(OH)-vitamin D₃. Journal of Steroid Biochemistry and Molecular Biology, 136(1), 59-61. DOI Scopus15 WoS12 Europe PMC8 |
2013 |
Kato, N., Matsumoto, M., Kogawa, M., Atkins, G., Findlay, D., Fujikawa, T., . . . Ogata, M. (2013). Critical role of p38 MAPK for regeneration of the sciatic nerve following crush injury in vivo. Journal of Neuroinflammation, 10(1), 1-13. DOI Scopus48 WoS42 Europe PMC49 |
2012 |
Aw, M., Khalid, K., Gulati, K., Atkins, G., Pivonka, P., Findlay, D., & Losic, D. (2012). Characterization of drug-release kinetics in trabecular bone from titania nanotube implants. International Journal of Nanomedicine (online), 7, 4883-4892. DOI Scopus53 WoS44 Europe PMC15 |
2012 |
Howie, D., Neale, S., Martin, W., Costi, K., Kane, T., Stamenkov, R., & Findlay, D. (2012). Progression of periacetabular osteolytic lesions. Journal of Bone and Joint Surgery-American Volume, 94(16), 1-6. DOI Scopus23 WoS3 Europe PMC15 |
2012 |
Atkins, G., & Findlay, D. (2012). Osteocyte regulation of bone mineral: a little give and take. Osteoporosis International, 23(8), 2067-2079. DOI Scopus132 WoS108 Europe PMC81 |
2012 |
Gulati, K., Aw, M., Findlay, D., & Losic, D. (2012). Local drug delivery to the bone by drug-releasing implants: perspectives of nano-engineered titania nanotube arrays. Therapeutic Delivery, 3(7), 857-873. DOI Scopus106 WoS93 Europe PMC27 |
2012 |
Alias, E., Dharmapatni, A., Holding, C., Atkins, G., Findlay, D., Howie, D., . . . Haynes, D. (2012). Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomaterialia, 8(8), 3104-3112. DOI Scopus20 WoS19 Europe PMC16 |
2012 |
Gulati, K., Ramakrishnan, S., Aw, M., Atkins, G., Findlay, D., & Losic, D. (2012). Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomaterialia, 8(1), 449-456. DOI Scopus271 WoS230 Europe PMC79 |
2011 |
Anderson, P., Atkins, G., Turner, A., Kogawa, M., Findlay, D., & Morris, H. (2011). Vitamin D metabolism within bone cells: Effects on bone structure and strength. Molecular and Cellular Endocrinology, 347(1-2 Sp Is), 42-47. DOI Scopus52 WoS49 Europe PMC26 |
2011 |
Wijenayaka, A., Kogawa, M., Lim, H., Bonewald, L., Findlay, D., & Atkins, G. (2011). Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One, 6(10), e25900-1-e25900-9. DOI Scopus406 WoS346 Europe PMC261 |
2011 |
Howie, D., Mc Gee, M., Callary, S., Carbone, A., Stamenkov, R., Bruce, W., & Findlay, D. (2011). A preclinical study of stem subsidence and graft incorporation after femoral impaction grafting using porous hydroxyapatite as a bone graft extender. Journal of Arthroplasty, 26(7), 1050-1056. DOI Scopus6 WoS4 Europe PMC4 |
2011 |
Findlay, D., & Atkins, G. (2011). Relationship between serum RANKL and RANKL in bone. Osteoporosis International, 22(10), 2597-2602. DOI Scopus62 WoS52 Europe PMC42 |
2011 |
Dharmapatni, A., Smith, M., Crotti, T., Holding, C., Vincent, C., Weedon, H., . . . Haynes, D. (2011). TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research & Therapy, 13(2), R51-1-R51-10. DOI Scopus35 WoS31 Europe PMC25 |
2011 |
Chehade, M., Vakaci, I., Callary, S., Findlay, D., & Solomon, L. (2011). Differentially loaded radiostereometric analysis (DLRSA) in torsion adds essential information in diaphyseal bone healing: the example of a tibial osteotomy. Journal of Bioengineering & Biomedical Sciences, 2011, 1-5. DOI |
2011 |
Atkins, G., Haynes, D., Howie, D., & Findlay, D. (2011). Role of polyethylene particles in peri-prosthetic osteolysis: A review. World Journal of Orthopedics, 2(10), 93-101. DOI Scopus47 WoS32 Europe PMC25 |
2011 |
Atkins, G., Rowe, P., Lim, H., Welldon, K., Ormsby, R., Wijenayaka, A., . . . Findlay, D. (2011). Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. Journal of Bone and Mineral Research, 26(7), 1425-1436. DOI Scopus209 WoS185 Europe PMC148 |
2011 |
Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2011). Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of Bone and Mineral Research, 26(3), 630-643. DOI Scopus19 WoS18 Europe PMC17 |
2011 |
Turner, A., Tjahyono, F., Chiu, W., Skinner, J., Sawyer, R., Moore, A., . . . Davey, R. (2011). The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone, 48(2), 354-361. DOI Scopus32 WoS30 Europe PMC17 |
2011 |
Findlay, D. M. (2011). DEBATE: IS SUBCHONDRAL BONE OR ARTICULAR CARTILAGE THE BEST TARGET FOR DMOAD DEVELOPMENT? BONE. OSTEOARTHRITIS AND CARTILAGE, 19, S4. DOI |
2010 |
Kogawa, M., Findlay, D., Anderson, P., Ormsby, R., Vincent, C., Morris, H., & Atkins, G. (2010). Osteoclastic metabolism of 25(OH)-vitamin D-3: A potential mechanism for optimization of bone resorption. Endocrinology, 151(10), 4613-4625. DOI Scopus125 WoS101 Europe PMC71 |
2010 |
Findlay, D. (2010). If good things come from above, do bad things come from below?. Arthritis Research & Therapy, 12(3), 119-1-119-2. DOI Scopus15 WoS15 Europe PMC12 |
2010 |
Labrinidis, A., Hay, S., Liapis, V., Findlay, D., & Evdokiou, A. (2010). Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model. International Journal of Cancer, 127(2), 345-354. DOI Scopus28 WoS25 Europe PMC20 |
2010 |
Kogawa, M., Anderson, P., Findlay, D., Morris, H., & Atkins, G. (2010). The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. Journal of Steroid Biochemistry and Molecular Biology, 121(1-2 Sp Iss), 277-280. DOI Scopus65 WoS52 Europe PMC29 |
2010 |
Stamenkov, R., Howie, D., Neale, S., Mc Gee, M., Taylor, D., & Findlay, D. (2010). Distribution of periacetabular osteolytic lesions varies according to component design. Journal of Arthroplasty, 25(6), 913-919. DOI Scopus6 WoS8 Europe PMC6 |
2009 |
Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molecular Cancer Therapeutics, 8(10), 2969-2980. DOI Scopus37 WoS38 Europe PMC29 |
2009 |
Atkins, G., Welldon, K., Wijenayaka, A., Bonewald, L., & Findlay, D. (2009). Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by y-carboxylation-dependent and -independent mechanisms. American Journal of Physiology-Cell Physiology, 297(6), C1358-C1367. DOI Scopus104 WoS98 Europe PMC73 |
2009 |
Vincent, C., Findlay, D., Welldon, K., Wijenayaka, A., Zheng, T., Haynes, D., . . . Atkins, G. (2009). Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNF alpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. Journal of Bone and Mineral Research, 24(8), 1434-1449. DOI Scopus152 WoS145 Europe PMC103 |
2009 |
Atkins, G., Welldon, K., Holding, C., Haynes, D., Howie, D., & Findlay, D. (2009). The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials, 30(22), 3672-3681. DOI Scopus85 WoS80 Europe PMC68 |
2009 |
Labrinidis, A., Hay, S., Liapis, V., Ponomarev, V., Findlay, D., & Evdokiou, A. (2009). Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clinical Cancer Research, 15(10), 3451-3461. DOI Scopus65 WoS58 Europe PMC44 |
2009 |
Dharmapatni, A., Smith, M., Findlay, D., Holding, C., Evdokiou, A., Ahern, M., . . . Haynes, D. (2009). Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Research & Therapy, 11(1), R13:1-R13:11. DOI Scopus53 WoS52 Europe PMC40 |
2009 |
Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009. DOI Scopus33 WoS30 Europe PMC27 |
2009 |
Vincent, C., Kogawa, M., Findlay, D., & Atkins, G. (2009). The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. Journal of Bone and Mineral Metabolism, 27(1), 114-119. DOI Scopus56 WoS49 Europe PMC37 |
2009 |
Atkins, G., Welldon, K., Halbout, P., & Findlay, D. (2009). Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporosis International, 20(4), 653-664. DOI Scopus173 WoS151 Europe PMC108 |
2009 |
Hopwood, B., Tsykin, A., Findlay, D., & Fazzalari, N. (2009). Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone, 44(1), 87-101. DOI Scopus94 WoS85 Europe PMC65 |
2008 |
Davey, R., Turner, A., McManus, J., Chiu, W., Tjahyono, F., Moore, A., . . . Zajac, J. (2008). Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. Journal of Bone and Mineral Research, 23(8), 1182-1193. DOI Scopus89 WoS73 Europe PMC41 |
2008 |
Findlay, D., Chehade, M., Tsangari, H., Neale, S., Hay, S., Hopwood, B., . . . Fazzalari, N. (2008). Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Research & Therapy, 10(1), 1-9. DOI Scopus27 WoS24 Europe PMC18 |
2008 |
Welldon, K., Atkins, G., Howie, D., & Finlay, D. (2008). Primary human osteoblasts grow into porous tantalum and maintain an osteoblastic phenotype. Journal of Biomedical Materials Research. Part A, 84A(3), 691-701. DOI Scopus85 WoS74 Europe PMC36 |
2008 |
Labrinidis, A., Liapis, V., Thai, L., Atkins, G., Vincent, C., Hay, S., . . . Evdokiou, A. (2008). Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?. Blood, 111(11), 5411-5412. DOI Scopus19 WoS15 Europe PMC8 |
2008 |
Fazzalari, N. L., Tsangari, H., Neale, S., Hay, S., Hopwood, B., Chehade, M., & Findlay, D. M. (2008). Relationship between bone RANKL MRNA levels and bone structural and turnover markers in male osteoarthritics. CALCIFIED TISSUE INTERNATIONAL, 82, S129. |
2007 |
Atkins, G. J., Welldon, K. J., & Findlay, D. M. (2007). Strontium ranelate promotes an osteocyte-like phenotype from human primary osteoblasts ex vivo. CALCIFIED TISSUE INTERNATIONAL, 80, S71-S72. |
2007 |
Atkins, G., Anderson, P., Findlay, D., Welldon, K., Vincent, C., Zannettino, A., . . . Morris, H. (2007). Metabolism of vitamin D₃ in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D₃. Bone, 40(6), 1517-1528. DOI Scopus217 WoS188 Europe PMC142 |
2007 |
Anderson, P., Atkins, G., Findlay, D., O'Loughlin, P., Welldon, K., Vincent, C., & Morris, H. (2007). RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)₂D₃ synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. Journal of Steroid Biochemistry and Molecular Biology, 103(3-5 Sp Iss), 601-605. DOI Scopus43 WoS34 Europe PMC19 |
2007 |
Tsangari, H., Findlay, D., & Fazzalari, N. (2007). Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood. Bone, 40(1), 211-217. DOI Scopus26 WoS26 Europe PMC18 |
2007 |
Howie, D., Neale, S., Stamenkov, R., Mc Gee, M., Taylor, D., & Findlay, D. (2007). Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. Journal of Bone and Joint Surgery-American Volume, 89A(8), 1818-1825. DOI Scopus52 WoS46 Europe PMC34 |
2007 |
Hopwood, B., Tsykin, A., Findlay, D., & Fazzalari, N. (2007). Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-β/bone morphogenic protein signalling. Arthritis Research & Therapy, 9(5), WWW 1-WWW 21. DOI Scopus168 WoS149 Europe PMC125 |
2007 |
Findlay, D. (2007). Vascular pathology and osteoarthritis. Rheumatology, 46(12), 1763-1768. DOI Scopus224 WoS178 Europe PMC141 |
2006 |
O'Neill, S., MacLennan, A., Bass, S., Diamond, T., Ebeling, P., Findlay, D., . . . Fiatarone-Singh, M. (2006). Wytyczne postępowania z osteoporozą omenopauzalną dla lekarzy rodzinnych. Lekarz Rodzinny, 4(104), 444-455. |
2006 |
Thai, L., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., Welldon, K., . . . Evdokiou, A. (2006). Apo21/tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Research, 66(10), 5363-5370. DOI Scopus30 WoS26 Europe PMC17 |
2006 |
Findlay, D. (2006). Regulation of cell growth mediated by the calcitonin receptor. Cellular and Molecular Biology, 52(3), 3-8. DOI Scopus8 WoS8 Europe PMC3 |
2006 |
Tsangari, H., Findlay, D., Zannettino, A., Pan, B., Kuliwaba, J., & Fazzalari, N. (2006). Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone, 39(6), 1226-1235. DOI Scopus19 WoS19 Europe PMC15 |
2006 |
Holding, C., Findlay, D., Stamenkov, R., Neale, S., Lucas, H., Dharmapatni, A., . . . Haynes, D. (2006). The correlation of RANK, RANKL and TNFα expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials, 27(30), 5212-5219. DOI Scopus111 WoS98 Europe PMC73 |
2006 |
Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Houchins, J., Findlay, D., . . . Zannettino, A. (2006). RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. Journal of Bone and Mineral Research, 21(9), 1339-1349. DOI Scopus111 WoS103 Europe PMC81 |
2006 |
Perper, S., Browning, B., Burkly, L., Weng, S., Gao, C., Giza, K., . . . Hess, H. (2006). TWEAK is a novel arthritogenic mediator. Journal of Immunology, 177(4), 2610-2620. DOI Scopus144 WoS134 Europe PMC97 |
2006 |
Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954. DOI Scopus72 WoS64 Europe PMC48 |
2005 |
Findlay, D., & Haynes, D. (2005). Mechanisms of bone loss in rheumatoid arthritis. Modern Rheumatology, 15(4), 232-240. DOI Scopus46 Europe PMC29 |
2005 |
Bouralexis, S., Findlay, D., & Evdokiou, A. (2005). Death to the bad buys: Targeting cancer via Apo2L/TRAIL. Apoptosis, 10(1), 35-51. DOI Scopus112 WoS107 Europe PMC71 |
2005 |
Zannettino, A., Holding, C., Diamond, P., Atkins, G., Kostakis, P., Farrugia, A., . . . Haynes, D. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 204(2), 714-723. DOI Scopus143 WoS141 Europe PMC97 |
2005 |
Atkins, G., Kostakis, P., Welldon, K., Vincent, C., Findlay, D., & Zannettino, A. (2005). Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 203(3), 573-582. DOI Scopus30 WoS29 Europe PMC24 |
2005 |
Kuliwaba, J., Fazzalari, N., & Findlay, D. (2005). Stability of RNA isolated from human trabecular bone at post-mortem and surgery. Biochimica et Biophysica Acta-Molecular Basis of Disease, 1740(1), 1-11. DOI Scopus36 WoS32 Europe PMC20 |
2005 |
Hopwood, B., Gronthos, S., Kuliwaba, J., Robey, P., Findlay, D., & Fazzalari, N. (2005). Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Bone, 36(4), 635-644. DOI Scopus21 WoS18 Europe PMC17 |
2005 |
Suva, L., Gaddy, D., Perrien, D., Thomas, R., & Findlay, D. (2005). Regulation of bone mass by mechanical loading: Microarchitecture and genetics. Current Osteoporosis Reports, 3(2), 46-51. DOI Scopus52 Europe PMC36 |
2004 |
O'Neill, S., MacLennan, A., Diamond, T., Ebeling, P., Findlay, D., Flicker, L., . . . Fiatarone-Singh, M. (2004). Guidelines for the management of postmenopausal osteoporosis for GPs. Australian Family Physician, 33(11), 910-919. Scopus35 Europe PMC18 |
2004 |
Findlay, D., & Sexton, P. (2004). Calcitonin. Growth Factors, 22(4), 217-224. DOI Scopus53 WoS45 Europe PMC23 |
2004 |
Crotti, T., Smith, M., Findlay, D., Zreiqat, H., Ahern, M., Weedon, H., . . . Haynes, D. (2004). Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NF[kappa]B, RANK ligand and osteoprotegerin. Biomaterials, 25(4), 565-573. DOI Scopus140 WoS124 Europe PMC103 |
2004 |
Mc Gee, M., Findlay, D., Howie, D., Carbone, A., Ward, P., Stamenkov, R., . . . Toth, C. (2004). The use of OP-1 in femoral impaction grafting in a sheep model. Journal of Orthopaedic Research, 22(5), 1008-1015. DOI Scopus53 WoS49 Europe PMC40 |
2004 |
Davey, R., MacLean, H., McManus, J., Findlay, D., & Zajac, J. (2004). Genetically modified animal models as tools for studying bone and mineral metabolism. Journal of Bone and Mineral Research, 19(6), 882-892. DOI Scopus33 WoS28 Europe PMC23 |
2004 |
Tsangari, H., Findlay, D., Kuliwaba, J., Atkins, G., & Fazzalari, N. (2004). Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone, 35(1), 334-342. DOI Scopus57 WoS54 Europe PMC39 |
2004 |
Bouralexis, S., Clayer, M., Atkins, G., Labrinidis, A., Hay, S., Graves, S., . . . Evdokiou, A. (2004). Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin. International Journal of Oncology, 24(5), 1263-1270. DOI Scopus14 WoS14 Europe PMC8 |
2004 |
Findlay, D., Welldon, K., Atkins, G., Howie, D., Zannettino, A., & Bobyn, D. (2004). The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 25(12), 2215-2227. DOI Scopus188 WoS161 Europe PMC72 |
2004 |
Pan, B., To, L., Farrugia, A., Findlay, D., Green, J., Gronthos, S., . . . Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 34(1), 112-123. DOI Scopus101 WoS91 Europe PMC67 |
2004 |
Pan, B., Farrugia, A., To, L., Findlay, D., Green, J., Lynch, K., & Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Journal of Bone and Mineral Research, 19(1), 147-154. DOI Scopus142 WoS129 Europe PMC102 |
2004 |
Hu, Y., Zhou, H., Myers, D., Quinn, J., Atkins, G., Ly, C., . . . Ng, K. (2004). Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. Journal of Bone and Mineral Research, 19(1), 89-99. DOI Scopus44 WoS39 Europe PMC32 |
2003 |
Atkins, G., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). RANKL expression is related to the differentiation state of human osteoblasts. Journal of Bone and Mineral Research, 18(6), 1088-1098. DOI Scopus213 WoS194 Europe PMC146 |
2003 |
Stamenkov, R., Howie, D., Taylor, J., Findlay, D., Mc Gee, M., Kourlis, G., . . . Burwell, M. (2003). Measurement of bone defects adjacent to acetabular components of hip replacement. Clinical Orthopaedics and Related Research, 412(412), 117-124. DOI Scopus39 WoS30 Europe PMC11 |
2003 |
Farrugia, A., Atkins, G., To, L., Pan, B., Horvath, N., Kostakis, P., . . . Zannettino, A. (2003). Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 63(17), 5438-5445. Scopus201 WoS185 Europe PMC138 |
2003 |
Evdokiou, A., Labrinidis, A., Bouralexis, S., Hay, S., & Findlay, D. (2003). Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone, 33(2), 216-228. DOI Scopus75 WoS70 Europe PMC49 |
2003 |
Bouralexis, S., Findlay, D., Atkins, G., Labrinidis, A., Hay, S., & Evdokiou, A. (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. British Journal of Cancer, 89(1), 206-214. DOI Scopus62 WoS59 Europe PMC36 |
2003 |
Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells. Blood, 102(11), 5207. |
2002 |
Atkins, G., Bouralexis, S., Evdokiou, A., Hay, S., Labrinidis, A., Zannettino, A., . . . Findlay, D. (2002). Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 31(4), 448-456. DOI Scopus60 WoS60 Europe PMC38 |
2002 |
Crotti, T., Smith, M., Weedon, H., Ahern, M., Findlay, D., Kraan, M., . . . Haynes, D. (2002). Receptor activator NFκB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Annals of the Rheumatic Diseases, 61(12), 1047-1054. DOI Scopus173 WoS153 Europe PMC118 |
2002 |
Findlay, D., Raggatt, L., Bouralexis, S., Hay, S., Atkins, G., & Evdokiou, A. (2002). Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism. Journal of Endocrinology, 175(3), 715-725. DOI Scopus20 WoS14 Europe PMC10 |
2002 |
Evdokiou, A., Bouralexis, S., Atkins, G., Chai, F., Hay, S., Clayer, M., & Findlay, D. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to APO2L/TRIAL-induced apoptosis. International Journal of Cancer, 99(4), 491-504. DOI Scopus132 WoS131 Europe PMC84 |
2002 |
O'Neill, S., Sambrook, P., Diamond, T., Ebeling, P., Ferris, L., Flicker, L., . . . Williamson, M. (2002). Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Australian Family Physician, 31(10), 921-928. Scopus9 Europe PMC3 |
2002 |
Atkins, G., Haynes, D., Zannettino, A., Capone, M., Crotti, T., & Findlay, D. (2002). Haemopoietic cells influence stromal cell gene expression during human osteoclast development. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 235. |
2002 |
Atkins, G., Crotti, T., Loric, M., Findlay, D., Howie, D., Bain, G., & Haynes, D. (2002). Periprosthetic osteolysis is associated with wear particles stimulating factors that control osteoclast formation. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 234. |
2002 |
Atkins, G., Crotti, T., Loric, M., Findlay, D., Smith, M., & Haynes, D. (2002). Osteolysis in bone loss pathologies is associated with similar factors that control osteoclast formation. Asia Pacific Orthopaedic Association.. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 234-235. |
2002 |
O'Neill, S., Sambrook, P., Diamond, T., Ebeling, P., Ferris, L., Flicker, L., . . . Williamson, M. (2002). Guidelines for the treatment of postmenopausal osteoporosis for general practitioners.. Australian family physician, 31(10), 921-928. Scopus8 |
2001 |
Crotti, T. N., Smith, M. D., Weedon, H., Capone, M., Holding, C., Findlay, D. M., & Haynes, D. R. (2001). Osteoprotegerin (OPG) and RANKL expression in tissues near bone in diseases of pathological bone loss: A comparison of rheumatoid arthritis, prosthetic joint failure and periodontal disease.. JOURNAL OF BONE AND MINERAL RESEARCH, 16, S227. WoS1 |
2001 |
Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (2001). Gene expression in human cancellous bone is similar between skeletal sites.. JOURNAL OF BONE AND MINERAL RESEARCH, 16, S327. |
2001 |
Haynes, D., Crotti, T., Loric, M., Bain, G., Atkins, G., & Findlay, D. (2001). Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology, 40(6), 623-630. DOI Scopus188 WoS165 Europe PMC121 |
2001 |
Haynes, D., Crotti, T., Potter, A., Loric, M., Atkins, G., Howie, D., & Findlay, D. (2001). The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. Journal of Bone and Joint Surgery-British Volume, 83B(6), 902-911. DOI Scopus168 WoS137 Europe PMC101 |
2001 |
Fazzalari, N., Kuliwaba, J., Atkins, G., Forwood, M., & Findlay, D. (2001). The ratio of messenger RNA levels of receptor activator of nuclear factor kB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. Journal of Bone and Mineral Research, 16(6), 1015-1027. DOI Scopus118 WoS101 Europe PMC81 |
2001 |
Evdokiou, A., Atkins, G., Bouralexis, S., Hay, S., Raggatt, L., Cowled, P., . . . Findlay, D. (2001). Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. International Journal of Oncology, 19(3), 625-632. DOI Scopus23 WoS22 Europe PMC15 |
2001 |
Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., . . . Katayama, S. (2001). Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kB ligand and macrophage colony-stimulating factor. Endocrinology, 142(4), 1471-1478. DOI Scopus23 WoS16 Europe PMC11 |
2001 |
Atkins, G., Bouralexis, S., Haynes, D., Graves, S., Geary, S., Evdokiou, A., . . . Findlay, D. (2001). Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28(4), 370-377. DOI Scopus86 WoS82 Europe PMC55 |
2001 |
Fazzalari, N., Kuliwaba, J., Atkins, G., Forwood, M., & Findlay, D. (2001). Osteoclast differentiation factor is dominant in controlling the extent of bone resorption. Bone, 28(5), S160. DOI |
2001 |
Findlay, D., Bouralexis, S., Atkins, G., Chai, F., Hay, S., Clayer, M., & Evdokiou, A. (2001). Protection of normal human bone cells from Apo2L/TRAIL and chemotherapeutic drug combination-induced apoptosis. Bone, 28(5), S137. DOI |
2001 |
Atkins, G., Evdokiou, A., Bouralexis, S., Chai, F., Hay, S., Clayer, M., & Findlay, D. (2001). Chemotherapeutic drugs sensitise osteogenic sarcoma cells but not normal human bone cells to TRAIL-mediated apoptosis. Bone, 28(5), S82. |
2001 |
Clayer, M., Bouralexis, S., Evdokiou, A., Hay, S., Atkins, G., & Findlay, D. (2001). Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL. Journal of Orthopaedic Surgery, 9(2), 19-22. DOI Scopus18 Europe PMC10 |
2001 |
Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., . . . Katayama, S. (2001). Regulation of Calcitonin Receptor by Glucocorticoid in Human Osteoclast-Like Cells Prepared in VitroUsing Receptor Activator of Nuclear Factor-κB Ligand and Macrophage Colony-Stimulating Factor.. Endocrinology, 142(4), 1471-1478. DOI |
2000 |
Lawrence Riggs, B., Baron, R., Boyle, W. J., John Martin, T., Suda, T., Yasuda, H., . . . Zambonin-Zallone, A. M. (2000). Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. Bone, 27(6), 761-764. DOI Scopus20 Europe PMC9 |
2000 |
Atkins, G., Haynes, D., Graves, S., Evdokiou, A., Hay, S., Bouralexis, S., & Findlay, D. (2000). Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. Journal of Bone and Mineral Research, 15(4), 640-649. DOI Scopus162 WoS163 Europe PMC114 |
2000 |
Kitahama, S., Gibson, M., Hatzinikolas, G., Hay, S., Kuliwaba, J., Evdokiou, A., . . . Findlay, D. (2000). Expression of fibrillins and other microfibril-associated proteins in human bone and osteoblast-like cells. Bone, 27(1), 61-67. DOI Scopus57 WoS53 Europe PMC34 |
2000 |
Findlay, D., Atkins, G., Forwood, M., Kuliwaba, J., & Fazzalari, N. (2000). Enhanced expression of osteocalcin mRNA in human osteoarthritic trabecular bone of the proximal femur is associated with decreased expression of interleukin-6 and interleukin-11 mRNA. Journal of Bone and Mineral Research, 15(2), 332-341. DOI Scopus46 WoS43 Europe PMC36 |
2000 |
Raggatt, L., Evdokiou, A., & Findlay, D. (2000). Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. Journal of Endocrinology, 167(1), 93-105. DOI Scopus32 WoS25 Europe PMC11 |
2000 |
Evdokiou, A., Raggatt, L., Sakai, T., & Findlay, D. (2000). Identification of a novel calcitonin-response element in the promoter of the human p21 WAF1/CIP1 gene. Journal of Molecular Endocrinology, 25(2), 195-206. DOI Scopus12 WoS12 Europe PMC8 |
2000 |
Atkins, G., Haynes, D., Geary, S., Loric, M., Crotti, T., & Findlay, D. (2000). Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone, 26(6), 653-661. DOI Scopus69 WoS65 Europe PMC43 |
2000 |
Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (2000). A molecular histomorphometric study of osteoarthritic cancellous bone. JOURNAL OF BONE AND MINERAL RESEARCH, 15(4), 811. |
2000 |
Findlay, D. M., Bouralexis, S., Atkins, G. J., Hedi, L., Hay, S., & Evdokiou, A. (2000). TRAIL-induced apoptosis of osteogenic sarcoma and breast cancer cells.. JOURNAL OF BONE AND MINERAL RESEARCH, 15, S352. |
1999 |
Atkins, G. J., Haynes, D. R., Graves, S. E., Evdokiou, A., Hay, S., Bouralexis, S., . . . Findlay, D. M. (1999). Expression of osteoclast differentiation signals by stromal elements of giant cell tumours.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S176. WoS1 |
1999 |
Raggatt, L. J., Evdokiou, A., & Findlay, D. M. (1999). Activation of the insert negative human calcitonin receptor: Phosphorylation of MAP kinase and inhibition of cellular proliferation.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S319. |
1999 |
Kuliwaba, J. S., Findlay, D. M., Atkins, G. J., Forwood, M. R., & Fazzalari, N. L. (1999). Bone remodelling in osteoarthritic cancellous bone a molecular histomorphometric study.. JOURNAL OF BONE AND MINERAL RESEARCH, 14, S464. |
1999 |
Sexton, P. M., Findlay, D. M., & Martin, T. J. (1999). Calcitonin. Current Medicinal Chemistry, 6(11), 1067-1093. Scopus180 WoS150 Europe PMC87 |
1999 |
Haynes, D., Atkins, G., Loric, M., Crotti, T., Geary, S., & Findlay, D. (1999). Bidirectional signaling between stromal and hemopoietic cells regulates interleukin-1 expression during human osteoclast formation. Bone, 25(3), 269-278. DOI Scopus40 WoS34 Europe PMC25 |
1999 |
Puche, R. C., Thomas, D. M., Udagawa, N., Hards, D. K., Quinn, J. M. W., Moseley, J. M., . . . Best, J. D. (1999). Letters to the editor (multiple letters).. Bone, 25(2). |
1999 |
Evdokiou, A., Raggatt, L., Findlay, D., & Atkins, G. (1999). Calcitonin Receptor-Mediated Growth Suppression of HEK-293 Cells is Accompanied by Induction of p21 WAF1/CIP1 and G2/M Arrest. Molecular Endocrinology, 13(10), 1738-1750. DOI Scopus38 WoS34 Europe PMC21 |
1998 |
Thomas, D., Udagawa, N., Hards, D., Quinn, J., Moseley, J., Findlay, D., & Best, J. (1998). Insulin receptor expression in primary and cultured osteoclast-like cells. Bone, 23(3), 181-186. DOI Scopus82 Europe PMC62 |
1998 |
Celic, S., Katayama, Y., Chilco, P., Martin, T., & Findlay, D. (1998). Type 1 collagen influence on gene expression in UMR106-06 osteoblast-like cells is inhibited by genistein. Journal of Endocrinology, 158(3), 377-388. DOI Scopus31 WoS27 Europe PMC18 |
1998 |
Katayama, Y., House, C., Udagawa, N., Kazama, J., McFarland, R., Martin, T., & Findlay, D. (1998). Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. Journal of Cellular Physiology, 176(1), 179-187. DOI Scopus51 Europe PMC40 |
1998 |
Evdokiou, A., Raggatt, L., Atkins, G. J., & Findlay, D. M. (1998). Growth inhibition by calcitonin of HEK293 cells is accompanied by induction of p21/WAF1/CIP1 and G2/M arrest. MOLECULAR BIOLOGY OF THE CELL, 9, 484A. |
1997 |
Katayama, Y., Soulis, T., Cooper, M. E., Seeman, E., Nagata, N., Martin, T. J., & Findlay, D. M. (1997). Aminoguanidine treatment increases bone mineral density in STZ induced diabetic rats.. DIABETOLOGIA, 40, 2289. |
1997 |
Katayama, Y., Soulis, T., Cooper, M. E., Seeman, E., Nagata, N., Martin, T. J., & Findlay, D. M. (1997). Aminoguanidine treatment increases bone mineral density in streptozotocin (STZ)-induced diabetic rats: Possible role of age formation.. JOURNAL OF BONE AND MINERAL RESEARCH, 12, S650. |
1997 |
Suva, L. J., Flannery, M. S., Caulfield, M. P., Findlay, D. M., Jüppner, H., Goldring, S. R., . . . Chorev, M. (1997). Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor. Journal of Pharmacology and Experimental Therapeutics, 283(2), 876-884. Scopus18 Europe PMC10 |
1997 |
Gillespie, M., Thomas, R., Pu, Z. Y., Zhou, H., & Findlay, D. (1997). Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. International Journal of Cancer, 73(6), 812-815. DOI Scopus92 Europe PMC56 |
1997 |
Findlay, D., & Martin, T. (1997). Receptors of Calciotropic Hormones. Hormone and Metabolic Research, 29(3), 128-134. DOI Scopus15 Europe PMC6 |
1997 |
Findlay, D. (1997). Receptor regulation - food for thought. European Journal of Endocrinology, 137(3), 218-219. DOI |
1997 |
Katayama, Y., Celic, S., Nagata, N., Martin, T., & Findlay, D. (1997). Nonenzymatic Glycation of Type 1 Collagen Modifies Interaction With UMR 201-10B Preosteoblastic Cells. Bone, 21(1), 237-242. DOI Scopus26 Europe PMC11 |
1997 |
Wada, S., Udagawa, N., Akatsu, T., Nagata, N., Martin, T., & Findlay, D. (1997). Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology, 138(2), 521-529. DOI Scopus49 Europe PMC24 |
1996 |
Traianedes, K., Martin, T., & Findlay, D. (1996). Regulation of osteopontin expression by type 1 collagen in preosteoblastic UMR201 cells. Connective Tissue Research, 34(1), 63-74. DOI Scopus10 Europe PMC8 |
1996 |
Ikegame, M., Rakopoulos, M., Martin, T., Moseley, J., & Findlay, D. (1996). Effects of Continuous Calcitonin Treatment on Osteoclast-like Cell Development and Clacitonin Receptor Expression in Mouse Bone Marrow Cultures. Bone and Mineral Research, 11(4), 456-465. DOI Scopus41 Europe PMC13 |
1996 |
Udagawa, N., Chan, J., Wada, S., & Findlay, D. (1996). c-fos Antisense DNA Inhibits Proliferation of Osteoclast Progenitors in Osteoclast Developments but not Macrophage Differentiation In Vitro. Bone, 18(6), 511-516. DOI Scopus17 Europe PMC11 |
1996 |
Celic, S., Chilco, P., Zajac, J., Martin, T., & Findlay, D. (1996). A Type 1 collagen substrate increases PTH/PTHrP receptor MRNA expression and suppresses PTHrP mRNA expression in UMR106-06 osteoblast -like cells. Journal of Endocrinology, 150(2), 299-308. DOI Scopus19 Europe PMC9 |
1996 |
Wada, S., Udagawa, N., Nagata, N., Martin, T., & Findlay, D. (1996). Physiological Levels of Calcitonin Regulate the Mouse Osteoclast Calcitonin Receptor by a Protein Kinase A-Mediated Mechanism. Endocrinology, 137(1), 312-320. DOI Scopus49 Europe PMC22 |
1996 |
Findlay, D., Houssami, S., Christopoulos, G., & Sexton, P. (1996). Homologous Regulation of the Rat C1a Calcitonin Receptor (CTR) in Nonosteoclastic Cells is Independent of CTR Messenger Ribonucleic Acid Changes and Cyclis Adenosine 3', 5' -Monophospate-Dependent Protein Kinase Activation. Endocrinology, 137(11), 4576-4585. DOI Scopus10 Europe PMC4 |
1996 |
Wada, S., Udagawa, N., Nagata, N., Martin, T., & Findlay, D. (1996). Calcitonin Receptor Down-Regulation Relates to Calcitonin Resistance in Mature Mouse Osteoclasts. Endocrinology, 137(3), 1042-1048. DOI Scopus43 Europe PMC19 |
1995 |
Southey, M. C., Findlay, D. M., & Kemp, B. E. (1995). Regulation of membrane-associated tyrosine phosphatases in UMR 106.06 osteoblast-like cells. Biochemical Journal, 305(2), 485-490. DOI Scopus19 Europe PMC16 |
1995 |
Findlay, D. M., Houssami, S., Sexton, P. M., Brady, C. L., Martin, T. J., & Myers, D. E. (1995). Calcium inflow in cells transfected with cloned rat and porcine calcitonin receptors. BBA - Molecular Cell Research, 1265(2-3), 213-219. DOI Scopus7 Europe PMC3 |
1995 |
Rakopoulos, M., Ikegame, M., Findlay, D. M., Martin, T. J., & Moseley, J. M. (1995). Short treatment of osteoclasts in bone marrow culture with calcitonin causes prolonged suppression of calcitonin receptor mRNA. Bone, 17(5), 447-453. DOI Scopus37 Europe PMC18 |
1995 |
Manji, S. S., Zhou, H., Findlay, D. M., Martin, T. J., & Ng, K. W. (1995). Tumor necrosis factor α facilitates nuclear actions of retinoic acid to regulate expression of the alkaline phosphatase gene in preosteoblasts. Journal of Biological Chemistry, 270(15), 8958-8962. DOI Scopus13 Europe PMC10 |
1995 |
Moore, E. E., Kuestner, R. E., Stroop, S. D., Grant, F. J., Matthewes, S. L., Brady, C. L., . . . Findlay, D. M. (1995). Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Molecular Endocrinology, 9(8), 959-968. DOI Scopus105 Europe PMC49 |
1995 |
Wada, S., Martin, T. J., & Findlay, D. M. (1995). Homologous regulation of the calcitonin receptor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocrinology, 136(6), 2611-2621. DOI Scopus57 Europe PMC26 |
1995 |
Ikegame, M., Rakopoulos, M., Zhou, H., Houssami, S., Martin, J. T., Moseley, J. M., & Findlay, D. M. (1995). Calcitonin receptor isoforms in mouse and rat osteoclasts. Journal of Bone and Mineral Research, 10(1), 59-65. DOI Scopus59 Europe PMC26 |
1995 |
Traianedes, K., Findlay, D. M., Martin, T. J., & Gillespie, M. T. (1995). Modulation of the signal recognition particle 54-kDa subunit (SRP54) in rat preosteoblasts by the extracellular matrix. Journal of Biological Chemistry, 270(36), 20891-20894. DOI Scopus10 Europe PMC7 |
1995 |
Houssami, S., Findlay, D. M., Brady, C. L., Martin, T. J., Epand, R. M., Moore, E. E., . . . Sexton, P. M. (1995). Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation. Molecular Pharmacology, 47(4), 798-809. Scopus51 Europe PMC21 |
1995 |
Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D. M., . . . Suda, T. (1995). Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Journal of Experimental Medicine, 182(5), 1461-1468. DOI Scopus352 Europe PMC208 |
1994 |
Sexton, P. M., Houssami, S., Brady, C. L., Myers, D. E., & Findlay, D. M. (1994). Amylin is an agonist of the renal porcine calcitonin receptor. Endocrinology, 134(5), 2103-2107. DOI Scopus28 Europe PMC9 |
1994 |
Houssami, S., Findlay, D. M., Hilton, J. M., O'Keeffe, L. M., Martin, T. J., & Sexton, P. M. (1994). Heterogeneity in ligand recognition of calcitonin receptors. Endocrine, 2(2), 127-134. Scopus16 |
1994 |
Findlay, D. M., Houssami, S., Lin, H. Y., Myers, D. E., Brady, C. L., Darcy, P. K., . . . Sexton, P. M. (1994). Truncation of the porcine calcitonin receptor cytoplasmic tail inhibits internalization and signal transduction but increases receptor affinity. Molecular Endocrinology, 8(12), 1691-1700. DOI Scopus43 Europe PMC21 |
1994 |
Houssami, S., Findlay, D. M., Brady, C. L., Myers, D. E., Martin, T. J., & Sexton, P. M. (1994). Isoforms of the rat calcitonin receptor: Consequences for ligand binding and signal transduction. Endocrinology, 135(1), 183-190. DOI Scopus94 Europe PMC45 |
1994 |
Zhou, H., Manji, S. S., Findlay, D. M., Martin, T. J., Heath, J. K., & Ng, K. W. (1994). Novel action of retinoic acid: Stabilization of newly synthesized alkaline phosphatase transcripts. Journal of Biological Chemistry, 269(35), 22433-22439. DOI Scopus52 Europe PMC30 |
1994 |
Kuestner, R. E., Elrod, R. D., Grant, F. J., Hagen, F. S., Kuijper, J. L., Matthewes, S. L., . . . Moore, E. E. (1994). Cloning and characterization of an abundant subtype of the human calcitonin receptor. Molecular Pharmacology, 46(2), 246-255. Scopus154 Europe PMC70 |
1993 |
Ikeda, K., Michelangeli, V. P., Martin, T. J., & Findlay, D. M. (1993). Type I collagen substrate increases calcitonin and parathyroid hormone receptor‐mediated signal transduction in UMR 106–06 osteoblast‐like cells. Journal of Cellular Physiology, 156(1), 130-137. DOI Scopus27 Europe PMC17 |
1993 |
Traianedes, K., Ng, K. W., Martin, T. J., & Findlay, D. M. (1993). Cell substratum modulates responses of preosteoblasts to retinoic acid. Journal of Cellular Physiology, 157(2), 243-252. DOI Scopus32 Europe PMC18 |
1993 |
Sexton, P. M., Houssami, S., Hilton, J. M., O'Keeffe, L. M., Center, R. J., Gillespie, M. T., . . . Findlay, D. M. (1993). Identification of brain isoforms of the rat calcitonin receptor. Molecular Endocrinology, 7(6), 815-821. DOI Scopus142 Europe PMC54 |
1993 |
Zhou, H., Hammonds, R. G., Findlay, D. M., Martin, T. J., & Ng, K. W. (1993). Differential effects of transforming growth factor‐β1 and bone morphogenetic protein 4 on gene expression and differentiated function of preosteoblasts. Journal of Cellular Physiology, 155(1), 112-119. DOI Scopus55 Europe PMC33 |
1992 |
Schneider, H. G., Michelangeli, V. P., Frampton, R. J., Grogan, J. L., Ikeda, K., Martin, T. J., & Findlay, D. M. (1992). Transforming growth factor-β modulates receptor binding of calciotropic hormones and G protein-mediated adenylate cyclase responses in osteoblast-like cells. Endocrinology, 131(3), 1383-1389. DOI Scopus45 Europe PMC28 |
1991 |
McQuillan, D. J., Findlay, D. M., Hocking, A. M., Yanagishita, M., Midura, R. J., & Hascall, V. C. (1991). Proteoglycans synthesized by an osteoblast-like cell line (UMR 106-01). Biochemical Journal, 277(1), 199-206. DOI Scopus28 Europe PMC20 |
1991 |
Zhou, H., Hammonds, G. R., Findlay, D. M., Fuller, P. J., Martin, J. T., & Ng, K. W. (1991). Retinoic acid modulation of mrna levels in malignant, nontransformed, and immortalized osteoblasts. Journal of Bone and Mineral Research, 6(7), 767-777. DOI Scopus77 Europe PMC46 |
1991 |
Kurokawa, M., Michelangeli, V. P., & Findlay, D. M. (1991). Induction of calcitonin receptor expression by glucocorticoids in T47D human breast cancer cells. Journal of Endocrinology, 130(2), 321-326. DOI Scopus19 Europe PMC9 |
1991 |
Schneider, H. G., Allan, E. H., Moseley, J. M., Martin, T. J., & Findlay, D. M. (1991). Specific down-regulation of parathyroid hormone (PTH) receptors and responses to PTH by tumour necrosis factor α and retinoic acid in UMR 106-06 osteoblast-like osteosarcoma cells. Biochemical Journal, 280(2), 451-457. DOI Scopus46 Europe PMC21 |
1991 |
Sexton, P. M., Schneider, H. G., D'Santos, C. S., Mendelsohn, F. A. O., Kemp, B. E., Moseley, J. M., . . . Findlay, D. M. (1991). Reversible calcitonin binding to solubilized sheep brain binding sites. Biochemical Journal, 273(1), 179-184. DOI Scopus15 Europe PMC8 |
1990 |
Thiebaud, D., Ng, K. W., Findlay, D. M., Harker, M., & Martin, T. J. (1990). Insulinlike growth factor 1 regulates mRNA levels of osteonectin and pro‐α<inf>1</inf>(I)‐collagen in clonal preosteoblastic calvarial cells. Journal of Bone and Mineral Research, 5(7), 761-767. DOI Scopus28 Europe PMC17 |
1989 |
Ng, K. W., Manji, S. S., Young, M. F., & Findlay, D. M. (1989). Opposing Influences of Glucocorticoid and Retinoic Acid on Transcriptional Control in Preosteoblasts. Molecular Endocrinology, 3(12), 2079-2085. DOI Scopus61 Europe PMC43 |
1989 |
Findlay, D. M., Michelangeli, V. P., & Robinson, P. J. (1989). Protein kinase-c-induced down-regulation of calcitonin receptors and calcitonin-activated adenylate cyclase in T47D and BEN Cells. Endocrinology, 125(5), 2656-2663. DOI Scopus27 Europe PMC19 |
1989 |
Young, M. F., Findlay, D. M., Dominguez, P., Burbelo, P. D., McQuillan, C., Kopp, J. B., . . . Termine, J. D. (1989). Osteonectin promoter. DNA sequence analysis and S1 endonuclease site potentially associated with transcriptional control in bone cells. Journal of Biological Chemistry, 264(1), 450-456. DOI Scopus54 Europe PMC33 |
1988 |
Findlay, D. M., Fisher, L. W., McQuillan, C. I., Termine, J. D., & Young, M. F. (1988). Isolation of the Osteonectin Gene: Evidence That a Variable Region of the Osteonectin Molecule Is Encoded within One Exon. Biochemistry, 27(5), 1483-1489. DOI Scopus30 Europe PMC22 |
1987 |
Moseley, J. M., Findlay, D. M., Gorman, J. J., & Martin, T. J. (1987). Photoaffinity labeling of the calcitonin receptor. Pharmacology and Therapeutics, 34(1), 51-58. DOI Scopus1 Europe PMC2 |
1986 |
Cosolo, W., Christophidis, N., Drummer, O. H., & Findlay, D. M. (1986). STUDIES ON THE CYTOTOXICITY OF PENICILLAMINE IN A RAT OSTEOGENIC SARCOMA. Clinical and Experimental Pharmacology and Physiology, 13(10), 737-743. DOI Scopus1 |
1986 |
Michelangeli, V. P., Findlay, D. M., Fletcher, A., & Martin, T. J. (1986). Calcitonin gene-related peptide (CGRP) acts independently of calcitonin on cyclic AMP formation in clonal osteogenic sarcoma cells (UMR 106-01). Calcified Tissue International, 39(1), 44-48. DOI Scopus44 Europe PMC27 |
1986 |
Findlay, D. M., & Martin, T. J. (1986). Kinetics of calcitonin receptor internalization in lung cancer (BEN) and osteogenic sarcoma (UMR 106–06) cells. Journal of Bone and Mineral Research, 1(3), 277-283. DOI Scopus28 Europe PMC10 |
1985 |
Findlay, D. M., Michelangeli, V. P., Martin, T. J., Orlowski, R. C., & Seyler, J. K. (1985). Conformational requirements for activity of salmon calcitonin. Endocrinology, 117(3), 801-805. DOI Scopus23 Europe PMC9 |
1985 |
Forrest, S. M., Ng, K. W., Findlay, D. M., Michelangeli, V. P., Livesey, S. A., Partridge, N. C., . . . Martin, T. J. (1985). Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcified Tissue International, 37(1), 51-56. DOI Scopus170 Europe PMC99 |
1984 |
Findlay, D. M., & Martin, T. J. (1984). Relationship between internalization and calcitonin induced receptor loss in T 47D cells. Endocrinology, 115(1), 78-83. DOI Scopus34 Europe PMC20 |
1983 |
Michelangeli, V. P., Findlay, D. M., Moseley, J. M., & Martin, T. J. (1983). Mechanisms of calcitonin induction of prolonged activation of adenylate cyclase in human cancer cells. Journal of Cyclic Nucleotide and Protein Phosphorylation Research, 9(2), 129-142. Scopus27 Europe PMC7 |
1983 |
Findlay, D. M., Michelangeli, V. P., Orlowski, R. C., & Martin, T. J. (1983). Biological activities and receptor interactions of des-leu<sup>16</sup> salmon and des-phe<sup>16</sup> human calcitonin. Endocrinology, 112(4), 1288-1291. DOI Scopus30 Europe PMC24 |
1983 |
Moseley, J. M., Findlay, D. M., Gorman, J. J., Michelangeli, V. P., & Martin, T. J. (1983). The calcitonin receptor on T 47D breast cancer cells. Evidence for glycosylation. Biochemical Journal, 212(3), 609-616. DOI Scopus16 Europe PMC12 |
1982 |
Frampton, R. J., Suva, L. J., Eisman, J. A., Findlay, D. M., Moseley, J. M., Martin, T. J., & Moore, G. E. (1982). Presence of 1,25-Dihydroxyvitamin D<inf>3</inf> Receptors in Established Human Cancer Cell Lines in Culture. Cancer Research, 42(3), 1116-1119. Scopus147 Europe PMC67 |
1982 |
Findlay, D. M., Ng, K. W., Niall, M., & Martin, T. J. (1982). Processing of calcitonin and epidermal growth factor after binding to receptors in human breast cancer cells (T 47D). Biochemical Journal, 206(2), 343-350. DOI Scopus30 Europe PMC14 |
1982 |
Moseley, J. M., Findlay, D. M., & Martin, T. J. (1982). Covalent cross-linking of a photoactive derivative of calcitonin to human breast cancer cell receptors. Journal of Biological Chemistry, 257(10), 5846-5851. DOI Scopus24 Europe PMC19 |
1982 |
Moseley, J. M., Findlay, D. M., Martin, T. J., & Gorman, J. J. (1982). A biological active photoaffinity probe used in identification of the calcitonin receptor. Clinical and Experimental Pharmacology and Physiology, 9(5). |
1981 |
Findlay, D. M., Michelangeli, V. P., Moseley, J. M., & Martin, T. J. (1981). Calcitonin binding and degradation by two cultured human breast cancer cell lines (MCF 7 and T 47D). Biochemical Journal, 196(2), 513-520. DOI Scopus42 Europe PMC23 |
1981 |
Findlay, D. M., De Luise, M., Michelangeli, V. P., & Martin, T. J. (1981). Independent down-regulation of insulin and calcitonin receptors on a human tumour cell line. Journal of Endocrinology, 88(2), 271-281. DOI Scopus25 Europe PMC15 |
1981 |
Lamp, S. J., Findlay, D. M., & Moseley, J. M. (1981). Calcitonin responsive adenylate cyclase in human breast cancer cells. Clinical and Experimental Pharmacology and Physiology, 8(4), 397. |
1981 |
Lamp, S. J., Findlay, D. M., Moseley, J. M., & Martin, T. J. (1981). Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T 47D). Journal of Biological Chemistry, 256(23), 12269-12274. DOI Scopus67 Europe PMC31 |
1980 |
Martin, T. J., Findlay, D. M., MacIntyre, I., Eisman, J. A., Michelangeli, V. P., Moseley, J. M., & Partridge, N. C. (1980). Calcitonin receptors in a cloned human breast cancer cell line (MCF 7). Topics in Catalysis, 96(1), 150-156. DOI Scopus41 Europe PMC30 |
1980 |
Findlay, D. M., deLuise, M., Michelangeli, V. P., Martin, T. J., & Ellison, M. (1980). Properties of a calcitonin receptor and adenylate cyclase in ben cells, A human cancer cell line. Cancer Research, 40(4), 1311-1317. Scopus71 Europe PMC47 |
1980 |
Findlay, D. M., Micneiangell, V. P., Eisman, J. A., Framptor, R. J., Moseley, J. M., Lain, M., . . . Whitehead, R. (1980). Calcitonin and 1,25-Dihydroxyvitamin D<inf>3</inf> Receptors in Human Breast Cancer Cell Lines. Cancer Research, 40(12), 4764-4767. Scopus107 Europe PMC65 |
1979 |
Dudley, F. J., Alford, F. P., Chisholm, D. J., & Findlay, D. M. (1979). Effect of portasystemic venous shunt surgery on hyperglucagonaemia in cirrhosis: Paired studies of pre- and post-shunted subjects. Gut, 20(10), 817-824. DOI Scopus26 Europe PMC20 |
1979 |
ALFORD, F. P., DUDLEY, F. J., CHISHOLM, D. J., & FINDLAY, D. M. (1979). GLUCAGON METABOLISM IN NORMAL SUBJECTS AND IN CIRRHOTIC PATIENTS BEFORE AND AFTER PORTASYSTEMIC VENOUS SHUNT SURGERY. Clinical Endocrinology, 11(4), 413-424. DOI Scopus18 Europe PMC8 |
1979 |
Findlay, D. M., Omond, S., Alford, F. P., & Chisholm, D. J. (1979). Hyperglycemia and glucagon suppression: Possible importance of the vagus and enteric humoral factors. Journal of Clinical Endocrinology and Metabolism, 48(1), 13-16. DOI Scopus10 Europe PMC4 |
1978 |
Chisholm, D. J., Alford, F. P., Harewood, M. S., Findlay, D. M., & Gray, B. N. (1978). Nature and biologic activity of "extrapancreatic glucagon": Studies in pancreatectomized cats. Metabolism, 27(3), 261-273. DOI Scopus11 Europe PMC10 |
1977 |
PERRY‐KEENE, D. A., ALFORD., F. P., CHISHOLM., D. J., FINDLAY., D. M., LARKINS, R. G., & MARTIN, F. I. R. (1977). GLUCAGON AND DIABETES: I. THE FAILURE OF HYPERGLUCAGONAEMIA TO INFLUENCE THE RESPONSE OF ESTABLISHED DIABETIC KETOACIDOSIS TO THERAPY. Clinical Endocrinology, 6(6), 417-423. DOI Scopus4 Europe PMC1 |